Skip to main content

Table 1 Clinical characteristics from the University of East Anglia, UK (UEA), GU Biobank at UHN, Canada (UHN), Trinity College at Dublin, Ireland (Dublin)

From: A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

Patient clinical characteristics UEA UHN Dublin
n (%) 194 (48) 155 (38) 59 (14)
Benign 109 (56) 46 (30) 27 (46)
PCa 85 (44) 109 (70) 32 (54)
Gleason score
 6 17 (20) 64 (59) 15 (47)
 7 42 (49) 32 (29) 9 (28)
 8–10 26 (31) 13 (12) 8 (25)
Clinical T stage
 T1 38 (45) 91 (83) 20 (63)
 T2 14 (16) 16 (15) 11 (34)
 T3 19 (22) 2 (2) 1 (3)
 T4 14 (16) 0 0
% Biopsy cores positive for PCa
 Median 57% 20% 21%
 Range 7–100% 5–100% 6–100%
 Interquartile range 33%–100% 9%–38% 13%–43%
 N/A 9 1 0
Age at enrollment
 Median 67 64 65
 Range 42–85 37–83 46–80
 Interquartile range 62–73 57–69 58–71
PSA at presentation
 Median 8.4 5.8 5.9
 Range 0.2–277.3 0.01–67.31 0.5–248
 Interquartile range 5.8–12.2 3.97–9.07 3.85–8.64
Prostate volume
 Median 59.54 47  
 Range 21.08–244.6 16.05–127.0  
 Interquartile range 42.52–86.52 34–57  
 N/A 92 18 59
Perineural invasion
 Yes 28 11 4
 No 80 17 55
 N/A 86 127 0
CAPRA risk
 CAPRA low 10 (12) 57 (52) 13 (41)
 CAPRA intermediate 32 (38) 36 (33) 14 (44)
 CAPRA high 43 (51) 16 (15) 5 (16)
D’Amico risk
 D’Amico low 8 (9) 52 (48) 9 (28)
 D’Amico intermediate 29 (34) 39 (36) 13 (41)
 D’Amico high 48 (56) 18 (17) 10 (31)